UBS AM’s Aura Biosciences AURA Stock Holding History

UBS AM’s Portfolio AURA Stock Details AURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.1K	Hold	4,517	–	–	﹤0.01%	3034
2026 Q1	$30.2K	Buy	4,517 +2,924	+184%	+$16.8K	﹤0.01%	3057
2025 Q4	$8.68K	Buy	+1,593	New	+$9.46K	﹤0.01%	2878

Other funds holding AURA

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

UBS AM's AURA Position: Q2 2026 in Review

UBS AM held its Aura Biosciences (AURA) position steady in Q2 2026 at 4,517 shares worth $32.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3034.

UBS AM first reported a position in AURA in Q4 2025 and has held it in 3 quarters since. 146 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

UBS AM held 4,517 shares of Aura Biosciences worth $32.1K as of Q2 2026.
UBS AM left its Aura Biosciences share count unchanged in Q2 2026.
Aura Biosciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3034 holding.
UBS AM first reported a position in Aura Biosciences in Q4 2025 and has held it in 3 quarters since.
146 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.